Hi Jessie, I didnt think much of Cooks previous spin on the...

Hi Jessie,

I didnt think much of Cooks previous spin on the value of GSK as the one-stop-shop for flu. Heres evidence that GSK can maintain their pandemic sales, by pushing more relenza in the mix. LANI may also do well with GSK as you suggest.

Im looking forward to this Qtr briefing. Analysts should query the impact of winding back GSKs vaccine sales and Witty will spin the boost in anti-viral sales. Be interesting to see how well the Japanese retail sales have done. Cheers,